NANOTYPE

EXPERIENCE THE FUTURE OF HLA TYPING

EARLY ACCESS PROGRAM

After testing more than 1000 samples internally and externally, we are ready for the next stage. Enroll to our Early Access Program and evaluate long-read sequencing with NanoTYPE HLA™ and benefit from an introductory price.

BENEFITS

PRODUCT HIGHLIGHTS

- High resolution – 3 fields
- Long-read sequencing
- Sample to sequencing in <4 hours*
- DNA samples to results in <5 hours for 1 sample*
- Minimal investment
- Simplified workflow compared to short-read NGS
- Flexible and scalable based on laboratory requirements from 1 to 24 samples per run

EXPERTS' FEEDBACK

"The technology is cost effective, scalable for the parallel typing of one-to-many samples, in a short period of time, providing excellent opportunities for the typing of deceased donors, elevating our matching capabilities to allow for epitope matching of these donors."

PROF. DIMITRI S. MONOS, PhD
Pathology and Laboratory Medicine
Perelman School of Medicine
University of Pennsylvania
The Children's Hospital of Philadelphia, USA

"We were astonished by the potential impact of this solution to enable sensitized patients to benefit from reliable epitope-based matching of deceased donors for the first time."

PROF. JEAN-LUC TAUPIN, PharmD, PhD
President of the Francophone Society of Histocompatibility and Immunogenetics
Immunology and Histocompatibility Laboratory,
Saint-Louis Hospital, AP-HP, Paris, France

"Overall, Nanopore sequencing is an excellent option for the future of HLA typing methodology."

DR. ANA M LAZARO-SHIBEN, PhD, CHS
Immunogenetics Laboratory
Johns Hopkins University School of Medicine, Baltimore, USA

EXPERIENCE THE FUTURE OF HLA TYPING

- Find suitable donors for highly sensitized patients faster
- Easy interpretation of results due to low ambiguities
- Intuitive software for genotyping analysis
- Prepare up to 12 samples and report results the next day
- No need for expensive investment and maintenance contract
- Save space in your lab due to the small footprint
- Easy on-boarding for non-NGS experts

WORKFLOW

*1 OR 12 SAMPLES



1

LONG-RANGE PCR

2h50min

2



RAPID LIBRARY PREPARATION

40min* - 1h40min



3

SEQUENCING

1h30min* - 12h

4

DATA ANALYSIS

2-5min per sample

APPLICATION

- Urgent typing
- Deceased donor typing
- Confirmatory typing
- Small series of samples
- Backup or replacement of NGS, SSO, RT-PCR

SOFTWARE ANALYSIS

Long-read sequences (N50 up to 4Kb) are analyzed using our intuitive and proprietary NanoTYPE HLA™ software.



Quality of runs are assessed using relevant metrics like

• **read quality** • **read length** • **coverage**



DATA EXPORT

Data are exported from NanoTYPE HLA™ software as JSON, PDF, HML, CSV, XML, TXT format and can be integrated into your LIM system.

BE PART OF THE EARLY ACCESS PROGRAM

Ready to step into the next level of HLA sequencing? Interested in trying our revolutionary new product, NanoTYPE HLA™, prior to other laboratories? Would you like to benefit from our Early Access Program? Do not hesitate anymore, instead, contact your local Omixon representative or our sales department at sales@omixon.com and we will provide you all the necessary information to start NanoTYPing with Omixon.

ABOUT US

Omixon is a global molecular diagnostic company serving more than 60 laboratories worldwide with operations in Europe and the US with the vision of transforming molecular biology innovations into state-of-the-art diagnostic products for transplant centers. By enabling transplant laboratories to bring the benefits of new technologies we improve transplant outcomes.
Our company uses its multidisciplinary competence ranging from bioinformatics, through software engineering to molecular diagnostics to provide cutting-edges solutions for various diagnostic problems relating to transplantation.
Omixon maintains an active research program with a product pipeline focused on pre- and post-transplant, and HLA genotyping applications beyond transplantation.

OMIXON AROUND THE WORLD

60+ LABS **25+** DISTRIBUTORS **5+** COUNTRIES WITH OMIXON REPRESENTATIVES



Albania, Australia, Belarus, Brazil, Bulgaria, Canada, Croatia, Czech Republic, Greece, Hungary, India, Israel, Italy, Japan, Kazakhstan, Kuwait, Mexico, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Switzerland, The Netherlands, UK, United Arab Emirates, Uruguay, USA

All Omixon activities covered by an ISO 13485:2016 & EN ISO 13485:2016 Quality Management System (QMS)

HEADQUARTER

OMIXON BIOCOMPUTING LTD.

Kaposvár u. 14-18
H-1117 Budapest
Hungary, EU

US BRANCH OFFICE

OMIXON INC.

Suite 265-F
100 Cummings Center
Beverly, MA 01915, USA

DISCLAIMER

The NanoTYPE EAP solution may vary from the final product with respect to allele coverage, protocol, software user interface. RUO Research Use Only Product - Not For Diagnostic Use

NANOTYPE

WORKFLOW MODEL 12 SAMPLES

Total Hands-On-Time: 1h50min | DNA to Sequencer: ~ 4h40min | DNA to Results: ~16h



1
LONG-RANGE PCR
PCR: 2h50min
Hands-On Time: 10min

2
RAPID LIBRARY PREPARATION
Library Prep: 1h40min

3
SEQUENCING
Sequencing Time: 12h

4
DATA ANALYSIS
Analysis Time: 2min/sample

NANOTYPE

WORKFLOW MODEL 1 SAMPLE

Total Hands-On-Time: 50min | DNA to Sequencer: ~ 3h40min | DNA to Results: ~5h



1
LONG-RANGE PCR
PCR: 2h50min
Hands-On Time: 10min

2
RAPID LIBRARY PREPARATION
Library Prep: 40min

3
SEQUENCING
Sequencing Time: 1h30min

4
DATA ANALYSIS
Analysis Time: 2min/sample